Cargando…
Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
INTRODUCTION: Natalizumab (NTZ) is an effective drug for the treatment of relapsing‐remitting multiple sclerosis. In some patients discontinuation is mandatory due to the risk of progressive multifocal leukoencephalopathy. However, severe clinical and radiological worsening has been described after...
Autores principales: | González‐Suarez, Inés, Rodríguez de Antonio, Luis, Orviz, Aida, Moreno‐García, Sara, Valle‐Arcos, María D., Matias‐Guiu, Jordi A., Valencia, Cristina, Jorquera Moya, Manuela, Oreja‐Guevara, Celia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390845/ https://www.ncbi.nlm.nih.gov/pubmed/28413713 http://dx.doi.org/10.1002/brb3.671 |
Ejemplares similares
-
Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021) -
Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging
por: Matías-Guiu, Jordi A., et al.
Publicado: (2016) -
Treatment with natalizumab during the Covid-19 pandemic in multiple sclerosis patients
por: Díaz-Díaz, Judit, et al.
Publicado: (2021) -
Functional Components of Cognitive Impairment in Multiple Sclerosis: A Cross-Sectional Investigation
por: Matias-Guiu, Jordi A., et al.
Publicado: (2017) -
Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)